# A Study of Baricitinib in Participants With Rheumatoid Arthritis

> **NCT04086745** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1317 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** TNF Inhibitor

## Key facts

- **NCT ID:** NCT04086745
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2025-05-19
- **Final completion:** 2025-05-19
- **Target enrollment:** 1317 (ACTUAL)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04086745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04086745, "A Study of Baricitinib in Participants With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04086745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*